6-thiouric acid profile

6-thiouric acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3032417
CHEMBL ID	3544573
CHEBI ID	80608
SCHEMBL ID	1282062
MeSH ID	M0055767

Synonym
nsc-46380
uric acid, 6-thio-
6-thiouric acid
1h-purine-2,6h)-dione, 7,9-dihydro-6-thioxo-
2002-60-0
nsc46380
6-thiourate
6-sulfanylidene-7,9-dihydro-3h-purine-2,8-dione
AKOS006273461
unii-7f23zqp3em
7f23zqp3em ,
1h-purine-2,8(3h,6h)-dione, 7,9-dihydro-6-thioxo-
nsc 46380
ai3-51991
uric acid, 6-thio- (van)
6-mercapto-9h-purine-2,8-diol
thiouric acid sodium salt dihydrate
AKOS015904793
2,8-dihydroxy-6-mercaptopurine
CHEBI:80608 ,
SCHEMBL1282062
6-mercapto-2,8-purinediol
DTXSID40173843
CHEMBL3544573
Q27149654
6-sulfanylidene-2,3,6,7,8,9-hexahydro-1h-purine-2,8-dione

Excerpt	Reference	Relevance
" 6-MP plasma concentrations in the patients were low (mean peak concentration 36."	( Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Ascher, NL; Canafax, DM; Chan, GL; Chen, S; Erdmann, GR; Gruber, SA; Stock, P, 1989)	0.6

Excerpt	Reference	Relevance
" Bioavailability of thiopurines may be competitively inhibited by dietary purines."	( Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Ansari, A; Aslam, Z; De Sica, A; Duley, J; Fairbanks, L; Gilshenan, K; Marinaki, A; Sanderson, J; Smith, M, 2008)	0.35

Class	Description
oxopurine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Azathioprine Action Pathway	47	82
Mercaptopurine Action Pathway	47	80
Thioguanine Action Pathway	47	81
Mercaptopurine Metabolism Pathway	15	24
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics	27	19
Drug ADME	63	87
Azathioprine ADME	16	26

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
UDP-glucose 6-dehydrogenase	Rattus norvegicus (Norway rat)	Ki	7.0000	7.0000	7.0000	7.0000	AID1520171
UDP-glucose 6-dehydrogenase	Streptococcus pyogenes	Ki	6.0000	5.0000	6.0000	7.0000	AID1575592; AID1575633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay ID	Title	Year	Journal	Article
AID1520184	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 10 uM after 45 mins in presence of UDPGA by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575590	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli/rat liver microsome UGT-1A assessed as reduction in BDG production at 5 uM in presence of UDPGA by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1575633	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli assessed as inhibitior constant after 20 to 120 secs by UV-VIS spectroscopic analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520173	Inhibition of UGT1A in rat hepatocytes preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520182	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 5 to 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575592	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli assessed as inhibitior constant by mesuring UDPGA production after 20 to 120 secs by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520190	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins in presence of regorafenib by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520171	Inhibition of UDPGDH in rat hepatocytes after 20 to 120 secs by UV/Vis spectrophotometric analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520177	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 5 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520180	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575593	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli/rat liver microsome UGT-1A assessed as reduction in BMG production at 5 uM by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520187	Inhibition of UGT1A in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520181	Inhibition of UDPGDH in rat hepatocytes assessed as increase in unconjugated bilirubin level at 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520178	Inhibition of UDPGDH in rat hepatocytes assessed as increase in unconjugated bilirubin level at 5 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520179	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575594	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli/rat liver microsome UGT-1A assessed as reduction in BDG production at 5 uM by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520186	Inhibition of UGT1A in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575637	Inhibition of UDPGDH/UGT-1A in hepatocytes (unknown origin) assessed as reduction in BMG production at 5 uM in presence of UDPGA by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520189	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins in presence of regorafenib by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520188	Inhibition of UGT1A in rat hepatocytes assessed as increase in unconjugated bilirubin level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520183	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 5 to 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520176	Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 5 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575639	Inhibition of UDPGDH/UGT-1A in hepatocytes (unknown origin) assessed as reduction in BDG production at 5 uM by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID1520172	Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	2019	MedChemComm, Jan-01, Volume: 10, Issue:1	Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575591	Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli/rat liver microsome UGT-1A assessed as reduction in BMG production at 5 uM in presence of UDPGA by HPLC analysis	2019	MedChemComm, May-01, Volume: 10, Issue:5	New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (28.57)	18.7374
1990's	7 (33.33)	18.2507
2000's	3 (14.29)	29.6817
2010's	5 (23.81)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (4.55%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (4.55%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.03	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	1.95	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.13	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
methylmercaptan methylmercaptan: intermediate in the manufacturing of jet fuels, pesticides, fungicides, plastics, synthesis of methionine; odor may cause nausea; narcotic in high concentrations; depresses urea biosynthesis; RN given refers to parent cpd; structure	2.13	1	0	alkanethiol	human metabolite; Saccharomyces cerevisiae metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	5.68	19	1	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.	2.03	1	0	xanthine	Saccharomyces cerevisiae metabolite
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	4.97	9	1	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
6-methylthiopurine 6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.	1.98	1	0	thiopurine
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	1.98	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.13	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.15	1	0
dimethyl disulfide [no description available]	2.13	1	0	organic disulfide	xenobiotic metabolite
dimethyl trisulfide [no description available]	2.13	1	0	organic trisulfide
mercury Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero.	1.95	1	0	elemental mercury; zinc group element atom	neurotoxin
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	5.57	17	1	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
6-thioxanthine 6-thioxanthine: gpt/6-TXenzyme/prodrug pair is a promising alternative to the thymidine kinase gene and ganciclovir combination in the gene therapy of cancer	2.49	2	0
thiouracil Thiouracil: Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.. thiouracil : A nucleobase analogue that is uracil in which the oxo group at C-2 is replaced by a thioxo group.	1.97	1	0	nucleobase analogue; thiocarbonyl compound	antithyroid drug; metabolite
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.37	7	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.15	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
aluminum Aluminum: A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.	1.97	1	0	boron group element atom; elemental aluminium; metal atom
6-chloropurine [no description available]	1.98	1	0	purines
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.37	1	1	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
regorafenib [no description available]	2.61	2	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
2',4',6'-tris(methoxymethoxy) chalcone 2',4',6'-tris(methoxymethoxy) chalcone: structure in first souce	2.21	1	0
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.93	4	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
2-amino-6-hydroxy-8-mercaptopurine [no description available]	2.03	1	0

Condition	Relationship Strength	Studies	Trials
Allergic Encephalomyelitis [description not available]	2.15	1	0
MS (Multiple Sclerosis) [description not available]	2.15	1	0
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.15	1	0
Colitis, Granulomatous [description not available]	2.04	1	0
Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.	2.04	1	0
Acute Lymphoid Leukemia [description not available]	2.05	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.05	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	3.37	1	1

6-thiouric acid

Description

Cross-References

Synonyms (26)

Research Excerpts

Pharmacokinetics

Bioavailability

Drug Classes (1)

Pathways (7)

Protein Targets (3)

Inhibition Measurements

Bioassays (25)

Research

Studies (21)

Market Indicators

Research Demand Index: 20.72

Study Types

6-thiouric acid

Description

Cross-References

Synonyms (26)

Research Excerpts

Pharmacokinetics

Bioavailability

Drug Classes (1)

Pathways (7)

Protein Targets (3)

Inhibition Measurements

Bioassays (25)

Research

Studies (21)

Market Indicators

Research Demand Index: 20.72

Study Types

Related Drugs (26)

Related Conditions (8)